Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Hedge Funds Make Big on Tekelec $TKLC

Tekelec (TKLC) shares rose 14.04% in trading on Monday. According to Reuters, the increase came on the realization that “the Siris Capital-led private equity takeover of network technology provider Tekelec could attract other suitors, as the $780 million deal potentially undervalues the company’s new router product line.” TKLC share prices rose from $9.90 at close on Friday to finish Monday at $11.29 a share.

Chuck Royce

The following hedge funds made the most:

1. Kensico Capital – Michael Lowenstein: Gained $9.7 million

2. Brookside Capital – Bain Capital: Gained $9.0 million

3. Intrepid Capital Management – Steve Shapiro: Gained $3.2 million

4. Royce & Associates – Chuck Royce: Gained $1.3 million

5. Ardsley Partners – Philip Hempleman: Gained $855,000

6. Millennium Management – Israel Englander: Gained $777,000

7. Courage Capital – Richard C. Patton: Gained $303,000

8. D E Shaw – D. E. Shaw: Gained $294,000

9. Catapult Capital Management – Israel Englander: Gained $271,000

10. Sac Capital Advisors – Steven Cohen: Gained $264,000

DISCLAIMER: These calculations assume that these hedge funds did not increase or reduce their stock positions in TKLC since the end of June. We did not take into account their option positions.

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!